Eli Lilly & Co. has received approval from European regulators for its Alzheimer's disease PET imaging agent Amyvid. The move allows the use of the agent in adults with cognitive impairment who are being assessed for Alzheimer's and related conditions. The agent should be available in Europe in the second quarter of the year.
Eli Lilly gets European OK for imaging agent Amyvid
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||